Analyst Price Target is GBX 0
This price target is based on 0 analysts offering 12 month price targets for Evgen Pharma in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a NaN upside from the last price of GBX 0.
Current Consensus is
N/A
The current consensus among 0 contributing investment analysts is to n/a stock in Evgen Pharma. This N/A consensus rating has held steady for over two years.
Evgen Pharma plc, a clinical stage drug development company, focuses on the development of sulforaphane-based medicines for the treatment of cancer and inflammatory diseases. It develops its products using Sulforadex, a sulforaphane stabilization technology. The company's lead product is SFX-01, that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase Ib/IIa clinical trials for the treatment of glioblastoma, as well as in preclinical stage for the treatment of haematological malignancies and analogues. It also provides out-licensing of its technology services. Evgen Pharma plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom.
Read More
